Evolution of Degenerative Myxomatous Mitral Valve Disease in a Canine Fox Terrier: A Case Report
Keywords:
degenerative myxomatous mitral valve disease pimobendan pulmonary edema
Abstract
Degenerative mitral valve disease (DMVD) consists of progressive degeneration of the mitral valve that can occur either in isolation or in association with the tricuspid valve, leading to incomplete coaptation of its leaflets and subsequent valve regurgitation. It's the most common cardiac condition in small animals, accounting for about 75% of cases of heart disease in dogs, mainly affecting elderly small-breed dogs. Breeds with a genetic predisposition, such as Cavalier King Charles Spaniels and Bull Terriers, tend to develop the disease early. It can be classified into four stages: A, B, C, and D, with B having subdivisions (B1 and B2). Animals in stages A, B1, and B2 are asymptomatic, showing clinical signs only from stage C onwards. The report details the case of a 13-year-old Fox Terrier diagnosed at stage B2 of the disease, progressing to stage C within two years-a cardiologist conducted annual monitoring.
Downloads
How to Cite
References
A Al-Mosawi (2023) Pharmacological Treatment of Chronic Symptomatic Premature Ventricular Contractions: An Educational Article and Expert Opinion. 6(2), 1-3.
A Boswood, J Häggström, S Gordon, G Wess, R Stepien, M Oyama, B Keene, J Bonagura, K Macdonald, M Patteson, S Smith, P Fox, K Sanderson, R Woolley, V Szatmári, P Menaut, W Church, M O'sullivan, J-P Jaudon, J-G Kresken, J Rush, K Barrett, S Rosenthal, A Saunders, I Ljungvall, M Deinert, E Bomassi, A Estrada, M Fernandez Del Palacio, N Moise, J Abbott, Y Fujii, A Spier, M Luethy, R Santilli, M Uechi, A Tidholm, P Watson (2016) Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study-A Randomized Clinical Trial. 30(6), 1765-1779.
Bruce Keene, Clarke Atkins, John Bonagura, Philip Fox, Jens Häggström, Virginia Fuentes, Mark Oyama, John Rush, Rebecca Stepien, Masami Uechi (2019) ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs. 33(3), 1127-1140.
Tahir; Khan, Roshan; Patel, Abdul Siddiqui (2018) Furosemide. Study Guide from StatPearls Publishing.
Maria Larsson, Matiko Helena, Akao (2023) Medicamentos antiarrítmicos. 7, 382-388.
Giulio Menciotti, Michele Borgarelli (2017) Review of Diagnostic and Therapeutic Approach to Canine Myxomatous Mitral Valve Disease. 4(4), 47.
Andrew Mcnair, Greg Markby, Qiyu Tang, Vicky Macrae, Brendan Corcoran (2023) TGF-β phospho antibody array identifies altered SMAD2, PI3K/AKT/SMAD, and RAC signaling contribute to the pathogenesis of myxomatous mitral valve disease. 10, 1202001.
A Pinkos, C Stauthammer (2021) Degenerative Valve Disease: Classification, Diagnosis, and Treatment of Mitral Regurgitation.
Lilian Petrus, Gimenes, ; André, Matheus Mantovani (2019) Degeneração mixomatosa Valvar. 9, 155-170.
Jim Riviere, Mark Papich, Booth (2021) Farmacologia e Terapêutica Veterinária.
Kátia Tárraga, Mitsube (2017) Anais do(a) Anais da escola de Nanotecnologia Aplicada à Farmacologia Veterinária & Simpósio Internacional de Farmacologia e Terapêutica Veterinária. 6, 503-512.
J Treseder, N Leblanc, K Scollan (2019) Inotropic and chronotropic effects of sotalol in healthy dogs. 25, 14-24.
Fernanda Yamaki, ; Lie, Rebecca Pessoa, Maria Bastos; Larsson, Matiko Helena, Akao (2023) Sistema cardiovascular: Arritmias cardíacas. 14, 1212-1237.
Published
2024-11-27
Issue
Section
License
Copyright (c) 2024 Authors and Global Journals Private Limited
This work is licensed under a Creative Commons Attribution 4.0 International License.